Dundee, UK –
22nd August 2018: Ubiquigent Limited, a company specializing in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched
REDOXprofiler™. The new service, validated following a collaboration with
Medivir AB, enables the rapid identification of REDOX cycling compounds (RCCs), which may generate false positive hits in drug discovery screening campaigns, particularly those targeting cysteine proteases including deubiquitylase (DUB) enzymes, cathepsins, caspases and protein tyrosine phosphatases.
REDOXprofiler™ provides a critical screening hit triage service, not only to those prosecuting DUB focussed drug discovery programmes, but beyond to include other cysteine protease focussed projects by rapidly identifying false positives, ensuring that the appropriate screening hits are followed up in hit-to-lead optimisation programmes.
REDOXprofiler™ has been designed primarily to complement and strengthen Ubiquigent’s existing DUB-targeted drug discovery service platform and capabilities but is equally valuable for identifying RCCs that may lead to the inactivation of the catalytic cysteine of any cysteine protease.
Ubiquigent’s Managing Director Jason Mundin commented: “With their highly regarded expertise in the field of cysteine protease directed drug discovery, we were delighted to work with Medivir AB in the evaluation and validation of REDOXprofiler™. We are now pleased to launch this service, which will complement our DUBprofiler™ selectivity service and further support the successful execution of our clients’ drug discovery programmes.”
To enquire about access to REDOXprofiler™ please contact Ubiquigent at services@ubiquigent.com
Contact
Ubiquigent Ltd
Jason Mundin
Managing Director
Email: jason.mundin@ubiquigent.com
Phone: +44 (0) 7976 000683
About Ubiquigent
Ubiquigent Limited is focused on enabling and supporting ubiquitin system drug discovery. Our biology and chemistry platforms allow us to design and develop novel compounds targeted towards ubiquitin system proteins as well as evaluate those of our partners.
Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Ubiquigent provides support to programmes at all stages from the provision of
Research Tools and reagents to assay development compound profiling
Drug Discovery Services through to larger
Collaborative Drug Discovery Programmes for the delivery of hit and lead compounds. At every stage Ubiquigent leverages its ubiquitin system focused knowledge and expertise to support is partners programmes.
Ubiquigent benefits from high-calibre backing, including from IP Group plc, US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers onsite), technological competencies, and assay and analytical platforms.
For more information, visit www.ubiquigent.com.
About the ubiquitin system
The
ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including cancer, cardiovascular and metabolic, neurological and musculoskeletal, and infection and immunity. Involving the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls), ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 30% of commercial drug discovery programmes target phosphorylation enzymes), and holds similar, if not greater, potential for clinical utility.
